AstraZeneca’s Oral GLP-1 Drug Shows Promise in Phase 2 Trials for Obesity and Diabetes

AstraZeneca’s investigational oral GLP-1 drug, elecoglipron, has demonstrated significant potential in phase 2 trials for both obesity and type 2 diabetes, according to data presented at the American Diabetes Association (ADA) conference. The findings, detailed in a February 2026 report by FierceBiotech, highlight the drug’s ability to reduce weight and improve glycemic control, though the company has not yet disclosed specific weight loss figures.

Phase 2 Trials: Weight Loss and Blood Sugar Control

In the Vista trial, which evaluated elecoglipron’s efficacy in patients with obesity or overweight, participants on the highest dose of the drug lost 11.2% of their body weight over 36 weeks. This result, presented at the ADA conference, underscores the drug’s potential as a treatment for weight management. However, AstraZeneca has not released detailed weight loss data from the study, citing plans to disclose the information at a later date.

Meanwhile, the Solstice trial focused on patients with type 2 diabetes. Those taking the highest dose of elecoglipron experienced a 1.74 percentage-point reduction in A1C levels—a key marker of blood sugar control—after 26 weeks. This improvement was compared to a 1.32 percentage-point reduction in patients taking oral Ozempic, a GLP-1 receptor agonist. The study, published in the Lancet, suggests that elecoglipron may offer competitive benefits for diabetes management.

Competitive Landscape and Future Development

AstraZeneca’s CEO, Pascal Soriot, emphasized the drug’s “very competitive profile” during the company’s 2025 earnings call, though he declined to provide direct comparisons to existing treatments. The company plans to advance elecoglipron into phase 3 trials in 2026, with regulatory submissions anticipated in the coming years. This follows the drug’s licensing from Eccogene in 2023, which provided AstraZeneca with rights to develop and commercialize elecoglipron.

The development of oral GLP-1 therapies represents a significant shift in the treatment of obesity and diabetes, as many current options require injections. AstraZeneca’s progress in this space positions it to challenge established players like Novo Nordisk, which has already launched oral GLP-1 drugs for weight loss. However, the lack of transparency around elecoglipron’s weight loss data may raise questions among investors and healthcare providers.

What’s Next for AstraZeneca’s Oral GLP-1?

Key questions remain about elecoglipron’s long-term efficacy, safety, and market positioning. The company’s decision to withhold weight loss data from the Vista trial until the ADA conference in June 2026 reflects the high stakes of competing in the obesity drug market. Analysts will be closely watching for further details, as well as comparisons to other emerging therapies, including Eli Lilly’s orforglipron, which has shown similar results in earlier trials.

As AstraZeneca prepares for phase 3 trials, the success of elecoglipron could reshape treatment paradigms for obesity and diabetes. However, the company will need to address lingering uncertainties about its drug’s performance relative to existing options and its potential to meet the demands of a rapidly evolving market.